Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Opevesostat · MK-5684, ODM-208

Small molecule · Inhibitor of cytochrome P450 side-chain cleavage enzyme (CYP11A1) (CYP11A1) · developed by Merck &

Phase 3 Most advanced trial
MRK Developer

What is Opevesostat?

Opevesostat is an orally bioavailable, non-steroidal, selective inhibitor of the mitochondrial enzyme CYP11A1, which converts cholesterol to pregnenolone, the first step in steroid hormone synthesis. By blocking this step it suppresses production of all steroid hormones and their precursors. It is being studied in metastatic prostate cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
MK-5684, ODM-208
Drug type
Small molecule
Targets
cytochrome P450 side-chain cleavage enzyme (CYP11A1) (CYP11A1)
Mechanism
Inhibitor of cytochrome P450 side-chain cleavage enzyme (CYP11A1) (CYP11A1)
Pathways
steroid hormone biosynthesis
Therapy area
Oncology
Developer
Merck & Co. (MRK)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
1Z7MAV4KQC

Conditions studied

Prostate Cancer Metastatic

More from Merck &

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the MRK page.

Follow MRK, the company behind Opevesostat

See MRK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

MRK catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.